FDA clears first new hep B vaccine in 25 years
The US Food and Drug Administration is allowing onto the market the first new hepatitis B vaccine in more than 25 years with the approval of Dynavax’ Heplisav-B.
Read More
Tag: Heplisav-B
FDA rejects Dynavax’ hepatitis B vaccine
Shares in US group Dynavax Technologies fell through the floor after US regulators refused to approve its flagship hepatitis B vaccine Heplisav-B.
Read More
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
